John L. Marshall, MD

Dr. Marshall on Genetic Testing in Gastrointestinal Cancer

October 5th 2022

John L. Marshall, MD, discusses the evolution of genetic testing in gastrointestinal cancer.

Dr. Marshall on Utilizing Precision Medicine in Bile Duct Cancer

March 31st 2022

John L. Marshall, MD, discusses potential next steps with research in bile duct cancer.

Dr. Marshall on the Results of the DESTINY-Gastric02 Trial in Gastric/GEJ Cancer

October 25th 2021

John L. Marshall, MD, discusses the results of the phase 2 DESTINY-Gastric02 trial in HER2-positive gastric and gastroesophageal junction cancers.

Dr. Marshall on Key Data from the DESTINY-Gastric02 Trial in HER2+ Gastric Cancer

October 15th 2021

John L. Marshall, MD, discusses key findings from the phase 2 DESTINY-Gastric02 trial examining fam-trastuzumab deruxtecan-nxki in patients with HER2-positive gastric cancer.

Dr. Marshall on the Importance of Molecular Profiling When Utilizing Precision Medicine

September 20th 2021

John L. Marshall, MD, discusses the importance of molecular profiling when utilizing precision medicine.

Dr. Marshall on Considerations for Third-Line Therapeutic Options in CRC

September 14th 2021

John L. Marshall, MD, discusses factors to consider in the third-line treatment setting for patients with colorectal cancer.

Dr. Marshall on the Push Toward Precision Medicine in CRC

April 8th 2020

John L. Marshall, MD, discusses the push toward precision medicine in colorectal cancer.

Dr. Marshall on Challenges in CRC Treatment

March 21st 2020

John L. Marshall, MD, discusses the challenges in the colorectal cancer field.

Dr. Marshall on Physician Burnout in Oncology

January 31st 2020

John L. Marshall, MD, discusses physician burnout in oncology.

Dr. Marshall on HER2 Amplification in Colorectal Cancer

April 8th 2019

John L. Marshall, MD, chief, Division of Hematology/Oncology, Medstar Georgetown University Hospital director, Otto J. Ruesch Center for the Cure of Gastrointestinal Cancer, Georgetown-Lombardi Comprehensive Cancer Center, discusses HER2 amplification in colorectal cancer (CRC).

Dr. Marshall on Personalized Chemotherapy in CRC

March 5th 2019

John L. Marshall, MD, chief, Division of Hematology/Oncology, Medstar Georgetown University Hospital director, Otto J. Ruesch Center for the Cure of Gastrointestinal Cancer, Georgetown-Lombardi Comprehensive Cancer Center, discusses personalized chemotherapy in the treatment of patients with colorectal cancer.

Dr. Marshall on Single-Agent and Combination Immunotherapy Applications in MSI-H mCRC

February 15th 2018

John L. Marshall, MD, chief, Division of Hematology/Oncology, Medstar Georgetown University Hospital director, Otto J. Ruesch Center for the Cure of Gastrointestinal Cancer, Georgetown-Lombardi Comprehensive Cancer Center, discusses the progression of immunotherapy in colon cancer.

Dr. Marshall on the Importance of Testing for BRAF Mutations in mCRC

February 12th 2018

John L. Marshall, MD, chief, Division of Hematology/Oncology, Medstar Georgetown University Hospital director, Otto J. Ruesch Center for the Cure of Gastrointestinal Cancer, discusses the specificity now required in the treatment of patients with metastatic colorectal cancer (mCRC).

Dr. Marshall Discusses Frontline Treatment for CRC

December 22nd 2017

John L. Marshall, MD, chief, Division of Hematology/Oncology, Medstar Georgetown University Hospital director, Otto J. Ruesch Center for the Cure of Gastrointestinal Cancer, discusses frontline treatment options for patients with colorectal cancer (CRC).

Dr. Marshall Discusses the State of RAS Mutations in GI Cancers

December 5th 2017

John L. Marshall, MD, chief, Division of Hematology/Oncology, Medstar Georgetown University Hospital director, Otto J. Ruesch Center for the Cure of Gastrointestinal Cancer, discusses the current state of RAS-mutant gastrointestinal (GI) cancers during the 2017 Ruesch Center Symposium.

Dr. Marshall on the Luminary Awards in GI Cancers

November 15th 2017

John L. Marshall, MD, chief, Division of Hematology/Oncology, Medstar Georgetown University Hospital director, Otto J. Ruesch Center for the Cure of Gastrointestinal Cancer, discusses the first annual Luminary Awards in GI Cancers, which is honoring five individuals who have devoted their time, talent and resources to improving the care for patients and families affected by GI cancers.

Dr. Marshall on Molecular Variances Between Right- Versus Left-Sided Colon Cancer

January 30th 2017

John L. Marshall, MD, chief, Division of Hematology/Oncology, Medstar Georgetown University Hospital, associate director, Clinical Research, Lombardi Comprehensive Cancer Center at Georgetown University Hospital, discusses molecular variances between right- and left-sided colon cancer.

Dr. Marshall on Y-90 Mechanism of Action in Liver-Dominant CRC

January 5th 2017

John L. Marshall, MD, chief, Division of Hematology and Oncology, Medstar Georgetown University Hospital, discusses the mechanism of action of Yttrium-90 in the treatment of patients with liver-dominant, metastatic colorectal cancer.

Dr. Marshall on Next Steps Following Y-90 in Liver-Metastatic CRC

December 17th 2016

John L. Marshall, MD, chief, Division of Hematology and Oncology, Medstar Georgetown University Hospital, and director, Otto J. Ruesch Center for the Cure of Gastrointestinal Cancers, discusses the next steps following the findings from the phase III SIRFLOX trial, which explored the addition of selective internal radiation therapy (SIRT), using Y-90 resin microspheres, to FOLFOX-based first-line chemotherapy in patients with liver-dominant metastatic colorectal cancer (mCRC).

Dr. Marshall on the Safety Profile of Y-90 in Colorectal Cancer

November 29th 2016

John L. Marshall, MD, chief, Division of Hematology and Oncology, Medstar Georgetown University Hospital, and director, Otto J. Ruesch Center for the Cure of Gastrointestinal Cancers, discusses the safety profile of Yttrium-90, particularly when combined with capecitabine as a treatment for patients with liver-dominant metastatic colorectal cancer.